Descriptor English: | Oxaliplatin | ||||||
Descriptor Spanish: |
Oxaliplatino
| ||||||
Descriptor Portuguese: | Oxaliplatina | ||||||
Descriptor French: | Oxaliplatine | ||||||
Entry term(s): |
1,2 Diaminocyclohexane Platinum Oxalate 1,2-Diaminocyclohexane Platinum Oxalate 1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II) ACT 078 ACT-078 ACT078 Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II) Eloxatin Eloxatine L-OHP Cpd Oxalato-(1,2-cyclohexanediamine)platinum II Oxaliplatin, (SP-4-2-(1R-trans))-isomer Oxaliplatin, (SP-4-2-(1S-trans))-isomer Oxaliplatin, (SP-4-3-(cis))-isomer Oxaliplatine Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) Platinum(II)-1,2-cyclohexanediamine Oxalate |
||||||
Tree number(s): |
D02.257.750 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D000077150 | ||||||
Scope note: | An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane, and with an oxalate ligand which is displaced to yield active oxaliplatin derivatives. These derivatives form inter- and intra-strand DNA crosslinks that inhibit DNA replication and transcription. Oxaliplatin is an antineoplastic agent that is often administered with FLUOROURACIL and FOLINIC ACID in the treatment of metastatic COLORECTAL NEOPLASMS. |
||||||
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
Pharm Action: |
Antineoplastic Agents |
||||||
Registry Number: | 04ZR38536J | ||||||
CAS Type 1 Name: | Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) | ||||||
Public MeSH Note: | 2019; OXALIPLATIN was indexed under ORGANOPLATINUM COMPOUNDS 1981-2018 |
||||||
History Note: | 2019 (1981) |
||||||
DeCS ID: | 57521 | ||||||
Unique ID: | D000077150 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 2019/01/01 | ||||||
Date of Entry: | 2018/07/09 | ||||||
Revision Date: | 2019/07/05 |
-
-
CHEMICALS AND DRUGS
Organic Chemicals [D02]Organic Chemicals
|
Oxaliplatin
- Preferred
Eloxatine
- Narrower
Eloxatin
- Narrower
Oxaliplatin, (SP-4-3-(cis))-isomer
- Narrower
ACT 078
- Narrower
Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II)
- Narrower
Oxaliplatin, (SP-4-2-(1S-trans))-isomer
- Narrower
Concept UI |
M0095550 |
Scope note | An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane, and with an oxalate ligand which is displaced to yield active oxaliplatin derivatives. These derivatives form inter- and intra-strand DNA crosslinks that inhibit DNA replication and transcription. Oxaliplatin is an antineoplastic agent that is often administered with FLUOROURACIL and FOLINIC ACID in the treatment of metastatic COLORECTAL NEOPLASMS. |
Preferred term | Oxaliplatin |
Entry term(s) |
1,2 Diaminocyclohexane Platinum Oxalate 1,2-Diaminocyclohexane Platinum Oxalate 1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II) L-OHP Cpd Oxalato-(1,2-cyclohexanediamine)platinum II Oxaliplatin, (SP-4-2-(1R-trans))-isomer Oxaliplatine Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) Platinum(II)-1,2-cyclohexanediamine Oxalate |
Concept UI |
M0433269 |
Preferred term | Eloxatine |
Concept UI |
M000639457 |
Preferred term | Eloxatin |
Concept UI |
M0318698 |
Preferred term | Oxaliplatin, (SP-4-3-(cis))-isomer |
Concept UI |
M0095545 |
Preferred term | ACT 078 |
Entry term(s) |
ACT-078 ACT078 |
Concept UI |
M0095547 |
Preferred term | Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II) |
Concept UI |
M0318696 |
Preferred term | Oxaliplatin, (SP-4-2-(1S-trans))-isomer |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey